Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer

Aung Ko Win, Mark A Jenkins, James G Dowty, Antonis C Antoniou, Andrew Lee, Graham G Giles, Daniel D Buchanan, Mark Clendenning, Christophe Rosty, Dennis J Ahnen, Stephen N Thibodeau, Graham Casey, Steven Gallinger, Loïc Le Marchand, Robert W Haile, John D Potter, Yingye Zheng, Noralane M Lindor, Polly A Newcomb, John L Hopper, Robert J MacInnis, Aung Ko Win, Mark A Jenkins, James G Dowty, Antonis C Antoniou, Andrew Lee, Graham G Giles, Daniel D Buchanan, Mark Clendenning, Christophe Rosty, Dennis J Ahnen, Stephen N Thibodeau, Graham Casey, Steven Gallinger, Loïc Le Marchand, Robert W Haile, John D Potter, Yingye Zheng, Noralane M Lindor, Polly A Newcomb, John L Hopper, Robert J MacInnis

Abstract

Background: Although high-risk mutations in identified major susceptibility genes (DNA mismatch repair genes and MUTYH) account for some familial aggregation of colorectal cancer, their population prevalence and the causes of the remaining familial aggregation are not known.Methods: We studied the families of 5,744 colorectal cancer cases (probands) recruited from population cancer registries in the United States, Canada, and Australia and screened probands for mutations in mismatch repair genes and MUTYH We conducted modified segregation analyses using the cancer history of first-degree relatives, conditional on the proband's age at diagnosis. We estimated the prevalence of mutations in the identified genes, the prevalence of HR for unidentified major gene mutations, and the variance of the residual polygenic component.Results: We estimated that 1 in 279 of the population carry mutations in mismatch repair genes (MLH1 = 1 in 1,946, MSH2 = 1 in 2,841, MSH6 = 1 in 758, PMS2 = 1 in 714), 1 in 45 carry mutations in MUTYH, and 1 in 504 carry mutations associated with an average 31-fold increased risk of colorectal cancer in unidentified major genes. The estimated polygenic variance was reduced by 30% to 50% after allowing for unidentified major genes and decreased from 3.3 for age <40 years to 0.5 for age ≥70 years (equivalent to sibling relative risks of 5.1 to 1.3, respectively).Conclusions: Unidentified major genes might explain one third to one half of the missing heritability of colorectal cancer.Impact: Our findings could aid gene discovery and development of better colorectal cancer risk prediction models. Cancer Epidemiol Biomarkers Prev; 26(3); 404-12. ©2016 AACR.

Conflict of interest statement

DISCLOSURE

The authors have no conflict of interest to declare with respect to this manuscript.

©2016 American Association for Cancer Research.

Figures

Figure 1
Figure 1
Amount of polygenic variance explained by the hypothetical unidentified major genes component (dark grey) and the polygenic component (white) for each 10-year age group.

References

    1. Taylor DP, Burt RW, Williams MS, Haug PJ, Cannon-Albright LA. Population-Based Family History-Specific Risks for Colorectal Cancer: A Constellation Approach. Gastroenterology. 2010;138:877–85.
    1. Rustgi AK. The genetics of hereditary colon cancer. Genes Dev. 2007;21:2525–38.
    1. Lynch HT, Snyder CL, Shaw TG, Heinen CD, Hitchins MP. Milestones of Lynch syndrome: 1895–2015. Nat Rev Cancer. 2015;15:181–94.
    1. Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet. 2009;41:112–7.
    1. Kovacs ME, Papp J, Szentirmay Z, Otto S, Olah E. Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome. Hum Mutat. 2009;30:197–203.
    1. Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, et al. Identification of FAP locus genes from chromosome 5q21. Science. 1991;253:661–5.
    1. Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science. 1991;253:665–9.
    1. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 1991;66:589–600.
    1. Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, Williams GT, et al. Inherited variants of MYH associated with somatic G:C –>T:A mutations in colorectal tumors. Nat Genet. 2002;30:227.
    1. Salovaara R, Loukola A, Kristo P, Kaariainen H, Ahtola H, Eskelinen M, et al. Population-Based Molecular Detection of Hereditary Nonpolyposis Colorectal Cancer. J Clin Oncol. 2000;18:2193–200.
    1. Dunlop MG, Farrington SM, Nicholl I, Aaltonen L, Petersen G, Porteous M, et al. Population carrier frequency of hMSH2 and hMLH1 mutations. Br J Cancer. 2000;83:1643–5.
    1. Terdiman JP. HNPCC: an uncommon but important diagnosis. Gastroenterology. 2001;121:1005–8.
    1. de la Chapelle A. The incidence of Lynch syndrome. Fam Cancer. 2005;4:233–7.
    1. Boland CR, Shike M. Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer. Gastroenterology. 2010;139:2197 e1–7.
    1. Hampel H, de la Chapelle A. The Search for Unaffected Individuals with Lynch Syndrome: Do the Ends Justify the Means? Cancer Prev Res. 2011;4:1–5.
    1. Song W, Gardner SA, Hovhannisyan H, Natalizio A, Weymouth KS, Chen W, et al. Exploring the landscape of pathogenic genetic variation in the ExAC population database: insights of relevance to variant classification. Genet Med. 2016;18:850–4.
    1. Aaltonen L, Johns L, Järvinen H, Mecklin J-P, Houlston R. Explaining the Familial Colorectal Cancer Risk Associated with Mismatch Repair (MMR)-Deficient and MMR-Stable Tumors. Clin Cancer Res. 2007;13:356–61.
    1. Jenkins MA, Baglietto L, Dite GS, Jolley DJ, Southey MC, Whitty J, et al. After hMSH2 and hMLH1–what next? Analysis of three-generational, population-based, early-onset colorectal cancer families. Int J Cancer. 2002;102:166–71.
    1. Chubb D, Broderick P, Dobbins SE, Frampton M, Kinnersley B, Penegar S, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nature communications. 2016;7:11883.
    1. Jenkins MA, Makalic E, Dowty JG, Schmidt DF, Dite GS, MacInnis RJ, et al. Quantifying the utility of single nucleotide polymorphisms to guide colorectal cancer screening. Future Oncol. 2016;12:503–13.
    1. Newcomb PA, Baron J, Cotterchio M, Gallinger S, Grove J, Haile R, et al. Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:2331–43.
    1. Colon Cancer Family Registry. Available from: .
    1. Colon Cancer Family Registry Questionnaires. Available from: .
    1. Southey MC, Jenkins MA, Mead L, Whitty J, Trivett M, Tesoriero AA, et al. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol. 2005;23:6524–32.
    1. Rumilla K, Schowalter KV, Lindor NM, Thomas BC, Mensink KA, Gallinger S, et al. Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases. J Mol Diagn. 2011;13:93–9.
    1. Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, et al. The Clinical Phenotype of Lynch Syndrome Due to Germ-Line PMS2 Mutations. Gastroenterology. 2008;135:419–28.
    1. Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29:1282–91.
    1. Arnold S, Buchanan DD, Barker M, Jaskowski L, Walsh MD, Birney G, et al. Classifying MLH1 and MSH2 variants using bioinformatic prediction, splicing assays, segregation, and tumor characteristics. Hum Mutat. 2009;30:757–70.
    1. InSiGHT variant databases. Available from:
    1. Thompson BA, Spurdle AB, Plazzer JP, Greenblatt MS, Akagi K, Al-Mulla F, et al. Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nat Genet. 2013;46:107–15.
    1. Cleary SP, Cotterchio M, Jenkins MA, Kim H, Bristow R, Green R, et al. Germline MutY Human Homologue Mutations and Colorectal Cancer: A Multisite Case-Control Study. Gastroenterology. 2009;136:1251–60.
    1. Dowty JG, Win AK, Buchanan DD, Lindor NM, Macrae FA, Clendenning M, et al. Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat. 2013;34:490–7.
    1. Baglietto L, Lindor NM, Dowty JG, White DM, Wagner A, Gomez Garcia EB, et al. Risks of Lynch Syndrome Cancers for MSH6 Mutation Carriers. J Natl Cancer Inst. 2010;102:193–201.
    1. Win AK, Dowty JG, Cleary SP, Kim H, Buchanan DD, Young JP, et al. Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology. 2014;146:1208–11.e1–5.
    1. Lange K. An approximate model of polygenic inheritance. Genetics. 1997;147:1423–30.
    1. Fernando RL, Stricker C, Elston RC. The finite polygenic mixed model: An alternative formulation for the mixed model of inheritance. Genetics. 1994;88:573–80.
    1. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al., editors. Cancer Incidence in Five Continents. IX. Lyon, France: International Agency for Research on Cancer; 2007.
    1. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med. 2009;11:42–65.
    1. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Control. 1974;19:716–23.
    1. Elston R. Models for discrimination between alternative modes of inheritance. In: Gianola D, Hammond F, editors. Advances in statistical methods for genetic improvement of livestock. Berlin: Springer; 1990. pp. 41–55.
    1. Antoniou AC, Pharoah PPD, Smith P, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer. 2004;91:1580–90.
    1. Win AK, Hopper JL, Jenkins MA. Association between monoallelic MUTYH mutation and colorectal cancer risk: a meta-regression analysis. Fam Cancer. 2011;10:1–9.
    1. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the missing heritability of complex diseases. Nature. 2009;461:747–53.
    1. Hopper JL, Mack TM. The heritability of prostate cancer-letter. Cancer Epidemiol Biomarkers Prev. 2015;24:878.
    1. Hopper JL, Carlin JB. Familial Aggregation of a Disease Consequent upon Correlation between Relatives in a Risk Factor Measured on a Continuous Scale. Am J Epidemiol. 1992;136:1138–47.
    1. Fisher RA. The correlation between relatives on the supposition of Mendelian inheritance. Transactions of the royal society of Edinburgh. 1918;52:399–433.
    1. MacInnis RJ, Severi G, Baglietto L, Dowty JG, Jenkins MA, Southey MC, et al. Population-based estimate of prostate cancer risk for carriers of the HOXB13 missense mutation G84E. PLoS One. 2013;8:e54727.
    1. Samadder NJ, Smith KR, Mineau GP, Pimentel R, Wong J, Boucher K, et al. Familial colorectal cancer risk by subsite of primary cancer: a population-based study in Utah. Aliment Pharmacol Ther. 2015
    1. Jang JH, Cotterchio M, Gallinger S, Knight JA, Daftary D. Family history of hormonal cancers and colorectal cancer risk: a case-control study conducted in Ontario. Int J Cancer. 2009;125:918–25.
    1. Nielsen M, van Steenbergen LN, Jones N, Vogt S, Vasen HFA, Morreau H, et al. Survival of MUTYH-Associated Polyposis Patients With Colorectal Cancer and Matched Control Colorectal Cancer Patients. J Natl Cancer Inst. 2010;102:1724–30.
    1. Watson P, Lin KM, Rodriguez-Bigas MA, Smyrk T, Lemon S, Shashidharan M, et al. Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members. Cancer. 1998;83:259–66.
    1. Sankila R, Aaltonen LA, Jarvinen HJ, Mecklin JP. Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology. 1996;110:682–7.
    1. Mai PL, Garceau AO, Graubard BI, Dunn M, McNeel TS, Gonsalves L, et al. Confirmation of family cancer history reported in a population-based survey. J Natl Cancer Inst. 2011;103:788–97.
    1. Giardiello FM, Welsh SB, Hamilton SR, Offerhaus GJ, Gittelsohn AM, Booker SV, et al. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med. 1987;316:1511–4.
    1. Haidle JL, Howe JR. Juvenile Polyposis Syndrome. In: Pagon RA, Bird TD, Dolan CR, Stephens K, editors. Gene Reviews. Seattle, WA: University of Washington, Seattle; 1993.
    1. Mallory SB. Cowden syndrome (multiple hamartoma syndrome) Dermatol Clin. 1995;13:27–31.
    1. Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet. 2013;45:136–44.
    1. Win AK, Young JP, Lindor NM, Tucker K, Ahnen D, Young GP, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol. 2012;30:958–64.
    1. Win AK, Hopper JL, Buchanan DD, Young JP, Tenesa A, Dowty JG, et al. Are the common genetic variants associated with colorectal cancer risk for DNA mismatch repair gene mutation carriers? Eur J Cancer. 2013;49:1578–87.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe